Zhu Jialiang, Lu Ziwen, Chen Wanbo, Ke Mang, Cai Xianguo
Department of Urology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, China.
Transl Androl Urol. 2022 Jan;11(1):67-78. doi: 10.21037/tau-21-1076.
This study aimed to systematically evaluate the efficacy of laparoscopic radical cystectomy (LRC) surgical therapy in patients with bladder cancer (BC), and to provide evidence for the clinical treatment of BC.
The Embase, Ovid, PubMed, Medline, Springer, and Web of Sciences database were searched to screen articles with clinical controlled trials on LRC treatment of BC. The Cochrane Handbook 5.0.2 software and Review Manager 5.3 software were adopted to evaluate the risk of bias and to perform a meta-analysis of the included articles in this study.
A total of 12 articles were obtained, including 1,283 research cases. The meta-analysis results showed that relative to the control group (Ctrl), the observation group (Observ group) had significantly lower intraoperative blood loss (IBL) after LRC [mean difference (MD) =-458.75; 95% confidential interval (CI): -505.75 to -411.76; Z=19.13; P<0.00001], blood transfusion rate (BTR) (odds ratio =0.36; 95% CI: 0.13-0.94; Z=2.08; and P=0.04), use of analgesics (MD =-24.53; 95% CI: -39.04 to -10.01; Z=3.31; and P=0.0009), and incidence of postoperative complications (Risk ratio =0.58; 95% CI: 0.39-0.85; Z=2.77; and P=0.006). However, and the length of hospital stay could not be shortened (MD =-2.43; 95% CI: -4.83 to -0.02; Z=1.98; and P=0.05).
LRC treatment of BC could effectively reduce the amount of IBS, and lower the intraoperative BTR, use of analgesics, and incidence of postoperative complications. Therefore, it could be used in the clinical surgical treatment of BC patients.
本研究旨在系统评价腹腔镜根治性膀胱切除术(LRC)治疗膀胱癌(BC)患者的疗效,为BC的临床治疗提供依据。
检索Embase、Ovid、PubMed、Medline、Springer和Web of Sciences数据库,筛选有关LRC治疗BC的临床对照试验文章。采用Cochrane手册5.0.2软件和Review Manager 5.3软件评估偏倚风险,并对本研究纳入的文章进行荟萃分析。
共获得12篇文章,包括1283例研究病例。荟萃分析结果显示,与对照组(Ctrl)相比,观察组(Observ组)LRC术后术中失血量(IBL)显著更低[平均差(MD)=-458.75;95%置信区间(CI):-505.75至-411.76;Z=19.13;P<0.00001]、输血率(BTR)(比值比=0.36;95%CI:0.13-0.94;Z=2.08;P=0.04)、镇痛药使用量(MD=-24.53;95%CI:-39.04至-10.01;Z=3.31;P=0.0009)及术后并发症发生率(风险比=0.58;95%CI:0.39-0.85;Z=2.77;P=0.006)。然而,住院时间未能缩短(MD=-2.43;95%CI:-4.83至-0.02;Z=1.98;P=0.05)。
LRC治疗BC可有效减少IBS量,降低术中BTR、镇痛药使用量及术后并发症发生率。因此,可用于BC患者的临床手术治疗。